<DOC>
	<DOCNO>NCT01650181</DOCNO>
	<brief_summary>Non-alcoholic steatohepatitis represent 10 - 15 % total case hepatic cirrhosis . In upcoming year , economic burden disease increase mean important problem health system due obesity epidemic . There several treatment non-alcoholic steatohepatitis ; however , none overcome healthy lifestyle include diet , exercise drug related insulin metabolism . There , use hepatoprotective drug antioxidant recommend eligible therapy reduce progression fatty liver steatohepatitis cirrhosis . Being approach experimental item yet also unavoidable reality . The purpose randomize control study explore effect siliphos-selenium-methionine-alpha lipoic acid + metformin versus metformin patient fatty liver non-alcoholic steatohepatitis biochemical echosonographic parameter .</brief_summary>
	<brief_title>Effects Siliphos-Selenium-Methionine-Alpha Lipoic Acid Patients With Fatty Liver Non-alcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>Patients Metabolic Syndrome accord ATP III Criteria Non smoker Without intake vitamin herbal medicine least one month Without uncontrolled glycemic level Compatible ultrasound and/or histological report Alcohol ingest &gt; 50 gr weekly chronic alcoholism Creatine serum &gt; 2 mg/dL Potassium serum &gt; 5.5 mEq/L Allergic metformin component study Pregnancy Anomalies blood coagulation liver anatomic Patients diseases and/or treatment cause fatty liver steatohepatitis Body weight change &gt; 10 % last 5 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>nafld , nash , fatty liver</keyword>
</DOC>